Gapping down
In reaction to earnings/guidance:
- AXTI -7.1% (lowers Q3 revenue guidance)
Other news:
- KALV -44.2% (announces termination of KVD824 Phase 2 Komplete trial for prophylactic treatment of hereditary angioedema)
- MRVI -7.2% (names Danaher exec as its new CEO)
- TYRA -5% (files for $400 mln mixed securities shelf offering)
- EHAB -3.1% (acquires hospice agency in Texas)
- PLTK -2.8% (Provides Update on Shares Tendered to Date in its Tender Offer for its Common Stock)
- RCKT -2.3% (prices offering of 6.8 mln shares of common stock at $14.75 per share)
- EVRI -0.8% (discloses that it has entered into an agreement to acquire certain strategic assets of Venuetize)